The closing price of Hims & Hers Health Inc (NYSE: HIMS) was $14.00 for the day, down -1.69% from the previous closing price of $14.24. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 6459594 shares were traded. HIMS stock price reached its highest trading level at $14.19 during the session, while it also had its lowest trading level at $12.75.
Ratios:
Our analysis of HIMS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 61.31. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $10.
On December 07, 2023, Imperial Capital started tracking the stock assigning a In-line rating and target price of $9.Imperial Capital initiated its In-line rating on December 07, 2023, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Okupe Oluyemi sold 50,574 shares for $13.55 per share. The transaction valued at 685,288 led to the insider holds 146,674 shares of the business.
Becklund Irene sold 17,930 shares of HIMS for $259,985 on Mar 04 ’24. The PAO now owns 2,747 shares after completing the transaction at $14.50 per share. On Mar 01 ’24, another insider, Dudum Andrew, who serves as the Chief Executive Officer of the company, sold 240,549 shares for $13.07 each. As a result, the insider received 3,144,120 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 3.05B and an Enterprise Value of 2.84B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.44 while its Price-to-Book (P/B) ratio in mrq is 8.69. Its current Enterprise Value per Revenue stands at 3.26 whereas that against EBITDA is -142.44.
Stock Price History:
The Beta on a monthly basis for HIMS is 0.88, which has changed by 49.27% over the last 52 weeks, in comparison to a change of 29.61% over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $14.89, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 9.61, while the 200-Day Moving Average is calculated to be 8.15.
Shares Statistics:
HIMS traded an average of 3.91M shares per day over the past three months and 10.58M shares per day over the past ten days. A total of 205.10M shares are outstanding, with a floating share count of 138.67M. Insiders hold about 35.28% of the company’s shares, while institutions hold 38.56% stake in the company. Shares short for HIMS as of Feb 15, 2024 were 13.47M with a Short Ratio of 3.44, compared to 15.21M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.31% and a Short% of Float of 8.47%.
Earnings Estimates
The firm’s stock currently is rated by 8 analysts. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.2, with 8 analysts recommending between $0.33 and $0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $271.65M to a low estimate of $250.8M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77M, an estimated increase of 40.70% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $285.57M, an increase of 39.30% less than the figure of $40.70% in the same quarter last year. There is a high estimate of $291.91M for the next quarter, whereas the lowest estimate is $260.1M.
A total of 11 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.07B, resulting in an average revenue estimate of $1.18B. In the same quarter a year ago, actual revenue was $878M, up 34.50% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $1.46B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.24B. The average revenue growth estimate for next year is up 23.90% from the average revenue estimate for this year.
